Vincerx Pharma, Inc. Announces Reverse Stock Split

Core Viewpoint - Vincerx Pharma, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective January 27, 2025, to reduce the number of issued shares and potentially enhance the stock price [1][2]. Summary by Sections Reverse Stock Split Details - The reverse stock split will convert every 20 issued shares into 1 issued share, reducing the total from approximately 44.8 million shares to about 2.2 million shares [2]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment instead [2]. - Adjustments will be made to the number of shares underlying outstanding equity awards, warrants, and other agreements [2]. Implementation and Process - Continental Stock Transfer & Trust Company will act as the exchange agent for the reverse stock split [3]. - Registered stockholders will have their positions automatically adjusted, while those with certificate shares will receive instructions from the exchange agent [3]. Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer [5]. - The company's pipeline includes several products in various stages of development, such as VIP943 in Phase 1 and VIP236, which has completed Phase 1 [5]. - Vincerx is headquartered in San Mateo, California, with a research facility in Monheim, Germany [6].